PURedit® Cas9 Flexible Cytosine Base Editor，30Y83，CAS9CBEFLX-30RXN，Sigma

General description

PURedit^® Cas9 Flexible Cytosine Base Editor has been engineered to achieve defined nucleotide changes of cytosine to thymine using RNP complex delivery. The PURedit^® Cas9 Flexible Cytosine Base Editor will edit cytosine residues from the third protospacer position to the 15th position (sixth position from the PAM). The base editor protein is recombinantly expressed in E. coli with 2X NLS. Uracil glycosylase inhibitor (UGI) protein, also recombinantly expressed in E. coli with 2X NLS, is included as a recommended optional component to enhance the rate of C-to-T editing and reduce the rate of other editing outcomes, including insertions and deletions (indels). UGI may be omitted to enable lower-frequency C-to-R (R = A or G) editing.


The kit contains:

• Cytosine Base Editor protein (CAS9CBEF) in 50% glycerol at 8 mg/mL
• Uracil glycosylase inhibitor (UGIPRT) in 50% glycerol at 15 mg/mL
• Transfection buffer (PEXBUF)
• Dilution buffer (DBUFFER)

Application

• Genome editing
• Functional genomics
• CRISPR screening
• Cell culture
• Embryos

Features and Benefits

Best in class protein offering of cytosine base editors. Safer gene editing without double stranded breaks allows for editing in sensitive cell lines and eliminates the risk of nonspecific donor DNA integration.

Precision Editing: high rates of C-to-T substitution at only the target site; reduced risks of off-target edits relative to plasmid or viral delivery.

Resource savings: screen fewer clones due to more predictable editing.

Legal Information

CRISPR Use License Agreement:
https://www.sigmaaldrich.com/US/en/life-science/legal/product-licenses/crispr-use-license-agreement
PURedit is a registered trademark of Merck KGaA, Darmstadt, Germany
PURedit is a registered trademark of Merck KGaA, Darmstadt, Germany